{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:03:17Z","timestamp":1787752997997,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":392,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jacc.2016.03.593","type":"journal-article","created":{"date-parts":[[2016,6,20]],"date-time":"2016-06-20T23:40:28Z","timestamp":1466466028000},"page":"2941-2948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure"],"prefix":"10.1016","volume":"67","author":[{"given":"Brett W.","family":"Sperry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Hachamovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Vranian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.03.593_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11886-015-0653-1","article-title":"Emerging advances in the management of cardiac amyloidosis","volume":"17","author":"Vranian","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2016.03.593_bib2","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jacc.2016.03.593_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A\u00a0trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine","volume":"336","author":"Kyle","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.03.593_bib4","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.03.593_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jacc.2016.03.593_bib6","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jacc.2016.03.593_bib7","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jacc.2016.03.593_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jacc.2016.03.593_bib9","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2016.03.593_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jacc.2016.03.593_bib11","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacc.2016.03.593_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2016.03.593_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jacc.2016.03.593_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ejh.12558","article-title":"Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment","volume":"96","author":"Gatt","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jacc.2016.03.593_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.03.593_bib16","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.03.593_bib17","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2016.03.593_bib18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2016.03.593_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","article-title":"Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib","volume":"88","author":"Hacihanefioglu","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jacc.2016.03.593_bib20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.110.010447","article-title":"Cardiac amyloidosis: a treatable disease, often overlooked","volume":"124","author":"Falk","year":"2011","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971632928X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971632928X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T03:29:23Z","timestamp":1536636563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971632928X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":20,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S073510971632928X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.03.593","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.03.593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}